GALECTIN THERAPEUTICS INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $6.5M | $11.7M | $15.3M | $13.1M | $8.4M | $5.7M | $4.5M | $3.6M |
| SG&A Expense | $7.1M | $4.5M | $6.2M | $7.0M | $7.0M | $6.4M | $5.4M | $6.9M |
| Operating Income | $-13.6M | $-16.2M | $-21.5M | $-20.1M | $-15.4M | $-12.1M | $-9.9M | $-10.4M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | $336.0K | $12.0K | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-13.9M | $-16.2M | $-21.4M | $-20.0M | $-15.8M | $-12.1M | $-9.7M | $-10.9M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.38 | $-0.49 | $-0.76 | $-0.88 | $-0.78 | $-1.30 | $-0.72 | $-1.06 |
| EPS (Diluted) | $-0.38 | $-0.49 | $-0.76 | $-0.88 | $-0.78 | $-1.30 | $-0.72 | $-1.06 |
| Shares Outstanding (Basic) | 41.2M | 35.8M | 32.9M | 28.8M | 22.3M | 18.4M | 16.1M | 12.9M |
| Shares Outstanding (Diluted) | 41.2M | 35.8M | 32.9M | 28.8M | 22.3M | 18.4M | 16.1M | 12.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |